Imbalanced Bone Turnover Markers and Low Bone Mineral Density in Patients with Osteonecrosis of the Femoral Head

Overview

Journal Int Orthop

Specialty Orthopedics

Date 2018 Mar 29

PMID 29589087

Citations 13

Authors

Lulu Tian

Seung-Hoon Baek

JinAn Jang

Shin-Yoon Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: There have been few studies investigating the cumulative effect of individual factors related to bone metabolism on the systemic balance between bone formation and resorption in patients with osteonecrosis of the femoral head (ONFH). We investigated bone mineral density (BMD) of lumbar spine and bone turnover markers that reflect systemic bone metabolism.

Methods: Two-hundred twenty patients with ONFH were matched to 220 healthy subjects according to age, gender, and body mass index. ONFH patients were divided into steroid-induced (18%), alcoholic (21%), and idiopathic ONFH (61%) and subgroup analysis was performed to exclude the effect of steroid and malnutrition on bone metabolism. We compared lumbar spine bone mineral density (BMD) between groups and measured serum bone-specific alkaline phosphatase (BALP) and urinary deoxypyridinoline/creatinine (Dpd/Cr) ratio.

Results: Logistic regression analysis revealed low spine BMD was significantly associated with each subgroup of ONFH when compared with that of the control group (odds ratio of 2.27, 4.24, and 1.86 in alcoholic, steroid, and idiopathic ONFH, respectively). The mean value of serum BALP (27.02 U/L) was within the normal reference range while average urine Dpd/Cr ratio (6.24 nM/mM) increased in ONFH group when compared with respective reference range.

Conclusion: Spine BMD decreased and urinary Dpd/Cr ratio increased in patients with non-traumatic ONFH. Further studies will be necessary to identify whether non-traumatic ONFH is merely a regional disease confined to the femoral head or may affect systemic bone metabolism.

Citing Articles

Bone biochemical markers, bone mineral density, and the risk of osteonecrosis of the femoral head: a Mendelian randomization study.

Jia H, Tian Z, Liang X, Li H, Lu B, Zhang J BMC Musculoskelet Disord. 2024; 25(1):996.

PMID: 39639283 PMC: 11619604. DOI: 10.1186/s12891-024-08130-5.

Clinical Characteristics, Current Treatment Options, Potential Mechanisms, Biomarkers, and Therapeutic Targets in Avascular Necrosis of Femoral Head.

Khanchandani P, Narayanan A, Naik A, Kannan V, Pradhan S, Srimadh Bhagavatham S Med Princ Pract. 2024; 33(6):519-536.

PMID: 39168116 PMC: 11631174. DOI: 10.1159/000541044.

Bioinformatics analysis of PANoptosis regulators in the diagnosis and subtyping of steroid-induced osteonecrosis of the femoral head.

Ding Q, Xiong B, Liu J, Rong X, Tian Z, Chen L Medicine (Baltimore). 2024; 103(18):e37837.

PMID: 38701259 PMC: 11062652. DOI: 10.1097/MD.0000000000037837.

Global research trends of steroid-induced osteonecrosis of the femoral head: A 30-year bibliometric analysis.

Lu C, Qi H, Xu H, Hao Y, Yang Z, Yu W Front Endocrinol (Lausanne). 2022; 13:1027603.

PMID: 36325458 PMC: 9618610. DOI: 10.3389/fendo.2022.1027603.

and Variants Were Correlated with Alcohol-Induced Femoral Head Necrosis Risk in the Chinese Han Population.

Liu C, Liu X, Li X Pharmgenomics Pers Med. 2022; 15:797-808.

PMID: 36110408 PMC: 9469939. DOI: 10.2147/PGPM.S369957.

References

Chang J, Ho M, Yeh C, Chen C, Wang G . Osteogenic gene expression decreases in stromal cells of patients with osteonecrosis. Clin Orthop Relat Res. 2006; 453:286-92. DOI: 10.1097/01.blo.0000238869.99980.b2. View

Hernigou P, Beaujean F . Abnormalities in the bone marrow of the iliac crest in patients who have osteonecrosis secondary to corticosteroid therapy or alcohol abuse. J Bone Joint Surg Am. 1997; 79(7):1047-53. DOI: 10.2106/00004623-199707000-00011. View

Tingart M, Beckmann J, Opolka A, Matsuura M, Wiech O, Grifka J . Influence of factors regulating bone formation and remodeling on bone quality in osteonecrosis of the femoral head. Calcif Tissue Int. 2008; 82(4):300-8. DOI: 10.1007/s00223-008-9111-z. View

Radke S, Battmann A, Jatzke S, Eulert J, Jakob F, Schutze N . Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head. J Orthop Res. 2006; 24(5):945-52. DOI: 10.1002/jor.20097. View

JONES Jr J . Fat embolism and osteonecrosis. Orthop Clin North Am. 1985; 16(4):595-633. View

Lai K, Shen W, Yang C, Shao C, Hsu J, Lin R . The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005; 87(10):2155-9. DOI: 10.2106/JBJS.D.02959. View

Civitelli R, Armamento-Villareal R, Napoli N . Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009; 20(6):843-51. DOI: 10.1007/s00198-009-0838-9. View

Maurel D, Boisseau N, Benhamou C, Jaffre C . Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int. 2011; 23(1):1-16. DOI: 10.1007/s00198-011-1787-7. View

Lukert B, Raisz L . Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990; 112(5):352-64. DOI: 10.7326/0003-4819-112-5-352. View

10.

Mont M, Jones L, Einhorn T, Hungerford D, Reddi A . Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Clin Orthop Relat Res. 1999; (355 Suppl):S314-35. View

11.

Terreni A, Pezzati P . Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab. 2012; 9(2):80-4. PMC: 3476515. View

12.

Kanis J, Gluer C . An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int. 2000; 11(3):192-202. DOI: 10.1007/s001980050281. View

13.

Karsenty G . How many factors are required to remodel bone?. Nat Med. 2000; 6(9):970-1. DOI: 10.1038/79655. View

14.

Yeh C, Chang J, Ho M, Chen C, Wang G . Different differentiation of stroma cells from patients with osteonecrosis: a pilot study. Clin Orthop Relat Res. 2009; 467(8):2159-67. PMC: 2706356. DOI: 10.1007/s11999-009-0803-0. View

15.

Hernigou P, Beaujean F, Lambotte J . Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br. 1999; 81(2):349-55. DOI: 10.1302/0301-620x.81b2.8818. View

16.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

17.

Agarwala S, Shah S, Joshi V . The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br. 2009; 91(8):1013-8. DOI: 10.1302/0301-620X.91B8.21518. View

18.

Matsuo K, Hirohata T, Sugioka Y, Ikeda M, Fukuda A . Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res. 1988; (234):115-23. View

19.

Hofstaetter J, Wang J, Yan J, Glimcher M . The effects of alendronate in the treatment of experimental osteonecrosis of the hip in adult rabbits. Osteoarthritis Cartilage. 2008; 17(3):362-70. DOI: 10.1016/j.joca.2008.07.013. View

20.

Lin T, Yan S, Cai X, Ying Z . Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int. 2011; 23(6):1823-34. DOI: 10.1007/s00198-011-1797-5. View